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Abstract 
 
Introduction: Medication reviews is a widely accepted approach known to have a 
substantial impact on patients’ pharmacotherapy and safety. Numerous options to optimise 
pharmacotherapy in older people have been reported in literature and they include 
medication reviews, computerised decision support systems, management teams, and 
educational approaches. Pharmacist-led medication reviews are increasingly being 
conducted, aimed at attaining patient safety and medication optimisation. Cost 
effectiveness is an essential aspect of a medication review evaluation.  
Areas covered: A systematic searching of articles that examined the cost-effectiveness of 
medication reviews conducted in aged care facilities was performed using the relevant 
databases. Pharmacist-led medication reviews confer many benefits such as attainment of 
biomarker targets for improved clinical outcomes, and other clinical parameters, as well as 
depict concrete financial advantages in terms of decrement in total medication costs and 
associated cost savings. 
Expert commentary: The cost-effectiveness of medication reviews are more consequential 
than ever before. A critical evaluation of pharmacist-led medication reviews in residential 
aged care facilities from an economical aspect is crucial in determining if the time, effort, 
and direct and indirect costs involved in the review rationalise the significance of conducting 
medication reviews for older people in aged care facilities.    
Keywords: Pharmacoeconomics  , Health Economics  , Pharmacist  , Pharmacy  , Agedcare 
facilities   
1. Introduction 
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Population aging is a global phenomenon. While population aging should be acknowledged 
as the outcome of successful healthcare, the aging society on its own represents a reign of 
challenges in any healthcare model [1]. There has been considerable concern pertaining the 
increased demand on the healthcare system and related costs [2]. The demand for 
healthcare services will exceed the population growth rate, given the disproportionate 
projected growth rate of older people. Consequently, a significant proportion of healthcare 
funds (30 to 60% of total healthcare costs) will be consumed by the older population [3-5]. 
The aging phenomenon has also led to an increase in hospital related admissions [6]. Older 
people residing in nursing homes consume four times more medicines compared to their 
aged-matched healthy counterparts in the community [7]; the prescribing of multiple 
medications is often an outcome of guideline-adherent care and this is associated with the 
addition of more medicines to achieve disease-specific targets [8]. This predisposes older 
patients to polypharmacy which is commonly defined as taking five or more medications [9]. 
The mean number of medications prescribed to each resident in the United Kingdom was 
4.4 in 1998 [10], 6.9 in 2003 [11], and 8.0 by 2007 [12]. Polypharmacy is also observed in 
approximately 80.0% of residents in aged care facilities in Australia [13]. In the United States, 
the Center of Medicare and Medicaid Services enacted a quality indicator measure directed 
at patients on nine or more medications; the 2004 United States Nursing Home Survey 
identified 39.7% residents with polypharmacy as defined by this quality indicator measure 
[14]. 
Polypharmacy among older people in nursing homes may be a risk factor to the increased 
healthcare expenditure as the medication cost for older people in developed countries 
account for a large proportion of the total healthcare expenditure [15]. Approximately 59.0% 
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of all medications dispensed in England were aimed at older people ≥60 years, with an 
estimated cost of £4.4 billion per annum on pharmaceutical ingredients only [16]. Hence it is 
pivotal that medication effectiveness (risk-benefit or rationalisation of use) is given 
precedence during the prescribing process [15]. This concern is amplified by the fact that 
about 50.0% of long-term medications have been reported to be inappropriate [17]. 
Evidently, polypharmacy is depicted as a strong predictor of potentially inappropriate 
medications (PIMs) [18]. 
Inappropriate medications or potentially inappropriate medications with regards to older 
people may be defined as “medications or medication classes that should generally be 
avoided in persons 65 years and older because they are either ineffective or they pose 
unnecessarily high risk for older persons and a safer alternative is available” [19]. The use of 
PIMs may increase the possibility of developing adverse drug reactions (ADRs), which could 
in turn lead to presentations at emergency departments of hospitals. Interestingly ADRs in 
at least one quarter of community-dwelling older people were preventable by avoiding PIMs 
[20]. Hospitalisations due to ADRs increased from approximately 13.0% among those 
prescribed two medications to 82.0% among those prescribed seven or more medications 
[21]. 
The cost of ADRs due to hospitalisations is multifactorial. The main costs of ADR in hospitals 
are many and they can be categorised as direct and indirect costs. Medications, disposable 
goods and wages form the foundation of the direct costs [22] whereas missed days from 
work or morbidity such as anxiety, as a result of ADR episodes, are the indirect costs [23]. 
The cost for preventable ADRs (e.g. avoiding the use of PIMs) has been estimated to be 
higher than that of non-preventable ADRs [24]. The cost per ADR in an inpatient setting was 
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reported as $US 2262; the inpatient ADR costs vary within different hospital wards, 
approximately $US 13,994 in a non-intensive care unit (non-ICU) and $US 19,685 in the ICU 
[25]. An extended duration of hospital stay and outpatient care because of ADRs inevitably 
contribute to healthcare’s financial burden [26].  
It is evident that medication optimisation in this population is crucial. Various interventions 
to optimise pharmacotherapy in older people residing in nursing homes have been 
described and evaluated in practice and reported in literature. They include medication 
reviews, pharmacist interventions, multidisciplinary team interventions, geriatric evaluation, 
computerised decision support systems, management teams, and educational approaches. 
Pharmacists have been in the forefront of many of these approaches [27]. 
Of the approaches that have proven beneficial in optimising medications, medication 
reviews offer many benefits [11, 28]. Medication review is defined as “a structured, critical 
examination of a patient’s medicines with the objective of reaching an agreement with the 
patient about treatment, optimising the impact of medicines, minimising the number of 
medication-related problems and reducing waste” [29]. The medication review process has 
been recognised to promote appropriate polypharmacy, decrease the use of inappropriate 
medications, aid in identification of possible and true drug-related adverse events; it also 
offers an opportunity to promote medication adherence [30]. 
Pharmacist-led medication reviews have formed the foundation of numerous intervention 
studies in the United Kingdom, the United States, Sweden, Switzerland, Norway, 
Netherlands, and Australia [31]. They are known as Residential Medication Management 
Review (RMMR) in Australia, Medication Therapy Management (MTM) in the United States, 
Medicines Use Review in the United Kingdom and New Zealand, and MedsCheck in Canada 
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[32-36]. These services are remunerated by the government or healthcare providers for 
individual items of service; they could also be bulk-funded or associated with capitation 
models. They are hence termed ‘fee-for-service’ pharmacist-led medication reviews [37]. 
Fee-for-service medication reviews led by pharmacists as part of their routine jobs are 
known to confer many benefits such as attainment of biomarker targets for improved 
clinical outcomes, reduced hospitalisations, reduced mortality, and improved quality of life 
[37]. Pharmacist-led medication reviews are aimed at attaining patient safety and are 
increasingly being conducted [38-40], particularly in aged care facilities, for the reasons 
discussed above. 
Hence a comprehensive summary of the current literature is crucial in determining the cost 
effectiveness of pharmacist-led medication reviews in nursing homes. This is pivotal in 
addressing two main issues: the rising healthcare costs on care for older people and the 
increasing rates of institutionalisation that urges the need for medication optimisation 
within this population. A critical evaluation of pharmacist-led medication reviews in 
residential aged care facilities from an economical aspect is crucial in determining if the time, 
effort, and direct and indirect costs involved in the review rationalise the significance of 
conducting a medication review for older people in aged care facilities.    
2. Cost-effectiveness of pharmacist-led medication reviews 
Cost effectiveness is an essential aspect of a medication review evaluation. Basic costs are 
relatively easy to identify and measure. Then again, the cost of prescribing extends beyond 
the cost of a medication listed on the prescription; the costs of the prescribing, dispensing 
and monitoring processes should be taken into consideration. Cost also comes into play 
when bodily biochemical repercussions occur while reviewing the outcome of starting, 
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stopping or switching brands of medications that may or may not cause ADRs. Cost also 
comes into play when a review is performed as an outcome of discontinuation of a 
medication, just as it would when the original medication is to be restarted for the patient 
or if switching to a more expensive alternative is deemed appropriate [15].  
3. Scope of the Review 
We assessed medication review based interventions conducted by pharmacists, aimed at 
improving medication cost savings in aged care settings. The PubMed (United States 
National Library of Medicine, Bethesda, MD, USA) and OVIDMEDLINE were searched 
between January 2000 and December 2015. References cited in the reference list of each 
identified original research or review article were scanned for any additional articles that 
would possibly be relevant to this review; these were subsequently also scanned for reviews 
and studies which may have been relevant and which were subject to the same eligibility 
evaluation.  
 
Two investigators (SSH and CSK) screened abstracts of articles published in English that 
evaluated (a) cost-effectiveness of medication review-based interventions in residential 
aged care facilities, (b) reports of pharmacist-led reviews in aged care facilities, and (c) 
outcome measures and impact of interventions on cost savings (medications). Studies 
focusing on clinical and/or educational approaches or interventions, and evaluations of 
cross-sectional or case series data were excluded, whereas randomised controlled trials, 
longitudinal studies, and those measuring pre and post medication review interventions 
were included. 
A total of 8 studies were ultimately included in the review, six observational studies and two 
randomised controlled trials. The researchers carefully assess the studies against a quality 
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checklist to estimate a quality of studies in terms of deficiencies. The 11-item checklist was consisted 
of questions related to design specific protection against bias (prospective vs retrospective), 
protection against selection bias (e.g. refusals, attrition), protection against information bias 
(adequate follow-up, accuracy of measurements of diabetes and depression) and adequate 
consideration of confounders. 
 
The eight studies evaluated the cost-effectiveness of medication review interventions in 
aged care facilities. Both RCTs were conducted in the United Kingdom. The observational 
studies (n = 6) used the following study designs: two prospective and four pre and post 
intervention studies. Of the six studies, three were conducted in the United States, and 1 
each in Switzerland, Singapore, and the United Kingdom. Medication reviews performed by 
pharmacists alone or in collaboration with other health care professionals result in 
significant drug cost savings. The studies evaluating cost-effectiveness of pharmacist-led 
medication reviews are summarised in Table 1. 
 
4. Cost-effectiveness of pharmacist-led medication review 
An eight-month prospective randomised controlled trial (four months of observation 
followed by four months of intervention) evaluated medication reviews by a pharmacist for 
older residents of fourteen nursing or residential homes (Furniss et al, 2000) [10]. One home 
in each pair was allocated using computer-generated pseudo-random numbers to receive 
either a regular medication review by a pharmacist (intervention group) or no medication 
review (control group). In the intervention group, the pharmacist suggested medication 
changes for each resident after collecting details of current medications from the 
medication chart, a brief medical history and current problems identified by the home staff. 
The homes were revisited three weeks after the medication review to ascertain if the 
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suggested changes had been implemented. The overall associated costs of all contacts with 
primary and secondary care resources were calculated for each home and divided by the 
number of residents in the study period to generate average costs per resident. At the end 
of the intervention phase, the average total costs per resident in the intervention arm was 
314.89 sterling pounds compared to 492.98 sterling pounds in the control group, a 
difference of 178.09 sterling pounds. This difference was mostly due to lower average costs 
for in-patient days per resident in the intervention arm (55.67 sterling pounds) compared to 
the control group (256.54 sterling pounds). Nevertheless, the authors could not perform a 
statistical comparison of these average costs because only fourteen homes in total could be 
included in this study.     
In 2004, Christensen et al. [28] determined the impact of a drug therapy management 
intervention program on nursing home drug costs. This program was designed by 
AccessCare Inc., a component organization of the Community Care of North Carolina (CCNC) 
program. The program involved a systematic drug regimen review by pharmacists during 
regular scheduled nursing home visits, and subsequent communication of recommendations 
to prescribing physicians and, to obtain results. To ensure consistency of the interventions, 
each pharmacist was provided with printed drug profiles of screened patients and a 
proprietary Toolkit which contained instructions for documenting consultations and 
explanations of the screening criteria which assisted the involved pharmacists in reviewing 
specific drug(s) or drug classes that possessed the potential to save costs. The first screening 
criterion was the Beers drug list, a list of drugs generally considered to be inappropriate for 
use in the elderly. The second screening criterion was the CCNC Prescription Advantage List 
(PAL) which prompts substitution of less expensive drugs within a therapeutic class. The list 
was further divided into drugs that offered no clear cost advantage (PAL-2) and would incur 
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significant costs (PAL-3). The third screening criterion was receipt of a drug on a list of 
clinical initiatives.  
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Table 1: Cost–effectiveness studies of medication reviews in the nursing homes 
Study (year) Study details Duration 
(months) 
Location Medication review type Cost-effectiveness 
Chia et al (2015) Design: pre-post review 
No of residents: 480 
No of homes: 3 
6 Singapore Clinical medication review by 
pharmacist 
Total cost savings 
Pre: SGD 388.30 
Post: SGD 876.69 
Baqir et al (2014) Design: pre-post review 
No. of residents: 422 
No of homes: 50 
12 UK Clinical review by 
multidisciplinary team with 
pharmacist 
Net annualised savings: £184 per person reviewed 
Brulhart et al (2011) Design: prospective (2007-
2009) 
No. of residents: 329 
No of homes: 10 
36 Switzerland Prescription review by 
pharmacist 
Intervention: annual decrement of drug costs: 14.6% 
Control: 0.1% decrement 
Trygstad et al (2009) Design: prospective records-
based 
No. of residents: 8087 
No of homes: 253 
3 USA Prescription review by 
pharmacist 
Drug-cost savings: USD21.63 per member per 
month 
Zermansky et al (2006) Design: RCT 
No. of residents: 661 
No of homes: 65 
1 UK Clinical medication review by 
pharmacist 
Cost of drugs per patient per 28 days: 
Intervention: £42.24 
Control: £42.94  
Trygstad et al (2005) Design: pre-post review 
No. of residents: 6344 
No of homes: 253 
 
6 USA Prescription review by 
pharmacist 
Median drug costs per resident: 
Intervention: decrement of USD 12.14 
Comparison: increment of USD 44.98 
Christensen et al (2004) Design: pre-post review 
No. of residents: 9208 
No of homes: 253 
 
3 USA Prescription review by 
pharmacist 
Mean drug regimen cost per patient per month: 
Post Intervention: USD 472.63 
Pre-intervention: USD 502.96 
Mean drug cost savings: $30.33 per patient per 
month 
Furniss et al (2000) Design: RCT 
No. of residents: 330 
No of homes: 14 
8 UK Clinical medication review Avg total costs per resident: 
Intervention: £314.89  
Control: £492.98 
Note:  1 USD = 0.76 sterling pounds; 1 USD = 1.36 SGD 
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Screening regimens with the Beers drug list resulted in significant mean drug cost savings of 
US dollar (USD) 2.49 per patient (p < 0.001). Screening with PAL-2 and PAL-3 lists resulted in 
a significant mean savings of USD 18.04 per patient and USD 18.94 per patient, respectively 
(p < 0.001). Screening with a clinical initiative list produced a significant mean saving of USD 
65.04 per patient. After taking all patients and all prescriptions into consideration, the mean 
drug regimen cost of each patient per month after intervention (USD 502.96) was 
significantly lower than before the intervention (USD 472.63), a mean reduction of USD 
30.33/patient per month (p < 0.001).      
In 2005, Trygstad et al. [38] assessed the impact of a focused drug therapy management 
intervention on drug costs from a payer perspective among nursing home residents with 
more than 18 prescription fills in 90 days. The intervention involved a drug utilisation review 
by consultant pharmacists who were provided with drug profiles of participating residents 
that displayed flags and suggestions for modifications of drugs and drug classes. These 
consultant pharmacists were required to conduct drug utilisation reviews during their 
regularly scheduled visits to each home, to communicate recommendations to prescribing 
physicians, and to follow through on outcomes of recommendations. The study utilised a 
before-after, study-comparison group design in which drug costs during the 3 months 
before and after the intervention were compared between study-group residents and 
comparison group residents. Study-group residents received a completed profile review by 
consultant pharmacists while the comparison group comprised of residents residing in 
nursing homes who were not included for the intervention.  
After the 3-month follow-up period, median drug costs per resident in the intervention 
group decreased from USD 1,329.46 to USD 1,317.32, with the amount of savings per 
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resident per month of USD 12.14 (p = 0.06). On the other hand, median drug costs per 
resident in the comparison group increased from USD 1,341.25 to USD 1,386.23, an 
increment of USD 44.98. This created a relative cost savings per resident of USD 57.12 or 
USD 19.04 per resident per month. When a subgroup of residents having documented 
profile reviews and recommendations resulting from the pharmacists’ consultation was 
analysed, a larger amount of savings per resident was observed with a median cost savings 
of USD 25.83 (p < 0.01). An even larger amount of savings per resident was observed in a 
subgroup of residents having a change in therapy as a result of a recommendation provided 
by consultant pharmacists with a median cost savings of USD 61.68 per resident (p < 0.01).  
In 2006, Zermansky et al. [11] reported an open randomised controlled trial of clinical 
medication review by a pharmacist of elderly care home (nursing, residential and mixed) 
residents taking at least one repeat medication against usual care to determine the cost of 
28 days of repeat medicines per participant as one of the secondary outcomes. Residents 
were randomised to receive either a clinical medication review by a pharmacist or usual 
care in randomly sized blocks of two to eight residents using a pre-determined algorithm. In 
the intervention arm, the study pharmacist performed a clinical medication review within 28 
days of randomisation which comprised a review of the general practitioner clinical records 
and a consultation with the resident and carer. The pharmacist-formulated 
recommendations were written on a proforma which was subsequently delivered to the 
treating general practitioner for acceptance and implementation. Residents in the control 
arm received usual medication reviews by a general practitioner. 
This study reported no significant difference (p> 0.05) in the cost of 28 days of repeat 
medicines per participant between intervention (42.24 sterling pounds) and control groups 
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(42.95 sterling pounds). Nevertheless, as indicated by the authors, the results did not 
suggest that clinical medication reviews by the pharmacist achieved no cost savings. More 
medications were discontinued in the intervention group, but such savings from drug 
discontinuation were offset by the additional costs incurred to address new therapeutic 
issues, turning cost-benefit into opportunity-benefit with no increase in overall medication 
cost. 
In 2009, Trygstad et al. [39] reported a prospective records-based study of the impact of 
large-scale medication therapy management in long-term care homes on drug costs. In the 
program, consultant pharmacists performed monthly retrospective drug regimen reviews 
for long-term residents. The program also had a prospective component in which consultant 
pharmacists could intervene and request for drug change as new medication orders came 
into the dispensing facility. To ensure equivalence among subjects, propensity scoring was 
used to match study subjects from participating long-term care homes with comparison 
counterparts from non-participating long-term care homes. While some residents received 
only retrospective reviews and interventions, some received only prospective interventions, 
and some received both types; residents with interventions were grouped for analysis by 
intervention type - retrospective only, prospective only, or dual type. Residents were further 
categorised by intervention stage - review, recommendation and drug change, which 
produced a total of 10 cohorts, including an all-inclusive grouping that aggregated groups by 
intervention type. Results are based on intention-to-treat analyses for all the cohorts. 
Overall, a significant drug-cost saving of USD 21.63 per member per month was observed (p 
< 0.05). These savings were observed at both the recommendation and drug-change levels, 
with USD 30.64 (p < 0.001) and USD 38.05 (p < 0.001) per member per month, respectively. 
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The drug-cost savings increased at intervention stages (retrospective only, prospective only, 
or dual type), closer to the drug-change stage (i.e. moving from [review] to [review and 
recommendation] to [review, recommendation, and drug change]). All 10 cohorts had 
statistically significant drug-cost savings (per member per month); residents with 
retrospective-only interventions at the drug-change level achieved the largest savings, i.e. 
USD 41.96 per member per month (p < 0.05). 
In 2011, Brulhart et al. [40] evaluated the economic impact of a pharmaceutical care 
intervention model for residents of nursing homes in a prospective study. The intervention 
model involved collection of medication use data and subsequent reviews by a pharmacist, 
focusing on drug indications, risk of medication errors, dosing, side effects, renal/hepatic 
elimination and drug-drug interactions. Identified drug-related problems and their proposed 
actions were then discussed with the physician and a nurse providing care. All residents in 
the participating nursing homes were randomly selected for inclusion in the study. The 
economic impact of the intervention was estimated via a retrospective evaluation of annual 
drug costs in participating nursing homes, three years pre and post intervention. The 
residents of the nursing homes in which medication reviews were not implemented during 
the study period, served as a control group for the economic evaluation.  
Over one thousand drug related problems were detected and discussed with the physician 
and the nurse during the study period. Medication review led to 343 medical evaluations 
secondary to drug-drug interactions and 803 treatment adaptations. This results in a 
definite decrement of annual drug costs of 14.6% in nursing homes with pharmacist-led 
medication reviews three years after implementation of the pharmaceutical care 
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interventions. The decrement was insignificant in the nursing homes with no medication 
review interventions, where only a 0.1% decrement in the annual drug costs was registered. 
In 2014, Baqir et al. [41] performed basic health economic evaluation of multidisciplinary 
medication reviews among residents of nursing homes involving pharmacists. The 
pharmacists first undertook a detailed medication review using primary care records, taking 
into account the indication, appropriateness, co-morbidities, residents (or carers’) views, 
and drug omission. Since the residents were under the care of different general practices, 
four subsequent working models with general practitioners were developed. In the first 
model, the general practitioners attended the multidisciplinary team meeting involving the 
care home nurses and decisions were jointly made with the care home nurses and 
pharmacists. In the second model, all interventions were discussed with the general 
practitioners following the medication reviews prior to the multidisciplinary team meeting. 
In the third model, all interventions were discussed with the general practitioners after the 
multidisciplinary team meeting prior to resident involvement. In the fourth model, the 
prescribing pharmacists led the intervention with no involvement of the general 
practitioners although general practitioners were allowed to challenge the interventions. 
Suggested interventions were then discussed with the residents and/or their family with the 
final decisions made jointly with the residents (or their family) where this was possible. 
Overall, costs paid for changing and starting medicines were 4,138 sterling pounds per 
annum while costs (~ 1 USD = 0.76 sterling pound) saved for changing or stopping medicines 
were 81,989 sterling pounds per annum. The net annualised saving was 77,702 sterling 
pounds or 184 sterling pounds per resident from the medicines budget. After considering 
the total cost of delivering the intervention (32,670 sterling pounds or 77.42 sterling pounds 
per resident), it was concluded that for every 1 sterling pound invested, 2.38 sterling pounds 
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could be saved. The savings against the medicines budget with the first model was £234 per 
resident per annum while cheapest service delivery was achieved with the fourth model 
without a general practitioner’s involvement (£58 per resident). For every 1 sterling pound 
invested, the greatest savings was achieved using the fourth model (£3.53 per resident) 
while the third model achieved the least savings (£1.30 per resident). The results of 
economic analysis revealed that the fourth model was more cost effective (i.e. more 
interventions and medicines stopped with less delivery cost) than the second and third 
models but less efficient than the first model (i.e. fewer interventions and medicines 
stopped with less delivery cost). 
In 2015, Chia et al. [42] reported a retrospective study to determine potential cost savings 
gained from pharmacist-led medication reviews in nursing homes. Data was collected during 
a one-month pre-setup period where the pharmacists performed medication reviews on all 
the enrolled residents and during a six-month post-setup period where the pharmacists 
performed weekly medication reviews on all the enrolled residents again. During the 
reviews, the pharmacists examined the medication records, case notes and medical charts 
as well as observed and interviewed the residents or nurses to better understand the 
residents’ conditions. In the pre-setup period, a written summary of pharmacotherapy 
problems identified during the medication reviews were handed to the general practitioners 
for their perusal. In the post-setup period, the pharmacists approached the general 
practitioners in their preferred ways to gain approval for their recommendations. Monthly 
cost savings as a result of drug discontinuations or substitutions following the medication 
reviews were calculated and compared with the monthly costs of pharmacist reviews to 
compute the net savings. 
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The average monthly costs of pharmacist reviews during the pre-setup period and post-
setup period were SGD 4,800 and SGD 800, respectively (~ 1 USD = 1.36 SGD). The monthly 
direct cost savings during the pre-setup period and post-setup period were SGD 388.30 and 
SGD 876.69, respectively. The mean cost savings per recommendation was SGD 12.94 
during the pre-setup period and SGD 19.06 during the post-setup period. When the costs of 
pharmacist reviews were factored in, the monthly direct cost savings during the pre-setup 
period were not enough to cover the cost of pharmacist reviews (SGD 4,800), with a 
negative net saving of –SGD 4,411.70. However, a positive net saving of SGD 76.69 per 
month was recorded during the post-setup period. 
5. Expert commentary 
The cost-effectiveness of medication reviews are more consequential than ever before. 
Despite the abundance in medical literature studies evaluating medication review services, 
only a handful discuss cost-effectiveness issues. Most of the published cost-effectiveness 
evaluations of medication review services involve medication reviews by pharmacists. The 
pharmacist-led medications reviews discussed above depict concrete financial advantages in 
terms of decrement in total medication costs and associated cost savings. For example, all 
three publications from the 2000 to 2014 period in the UK (included two RCTs) have 
depicted that medication reviews provided by the pharmacist are a superior service as 
opposed to no service or usual service in terms of drug cost savings. The cost savings in 
some studies were more apparent in the intervention group as opposed to the control 
group whereas in other studies the net savings did not vary much between both groups. 
However it must be acknowledged that drug cost savings do not automatically translate to 
reduction in healthcare costs (as it does not cover future hospitalisations, investigations, 
follow-ups etc.) and/ or improved patient outcomes. This thought-provoking phenomenon 
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can be comprehended in many ways, but we suggest exploring this occurrence in a domino 
theory-like approach, that will be discussed below.  
 
Firstly, it would be worthwhile to consider cost savings from the perspective of a patient, as 
older people are increasingly assuming the responsibility over their own healthcare. The 
value of their healthcare expense is perceived as a cost relationship between their out-of-
pocket expense and quality, which is largely equated with service [46]. This provides insight 
on the perception of patients that should be valued as it indirectly provides a potential 
solution in cost minimisation for healthcare. From the viewpoint of a nursing home setting, 
it is pertinent that older people are given the opportunity to empower their own health as 
many of them often portray diminished autonomy. It is best to seek practical solutions to 
improve the healthcare system such that it will provide older people with added healthcare 
value whilst minimising on cost.  
A defining tenet in the optimisation of pharmacotherapy for the older population is by 
adopting a patient-centred approach; this approach to healthcare could be perceived as a 
strong contender in the pursuit of cost-minimisation. Patient-centred care is defined as an 
approach to health care that is responsive to, and respectful of, the preferences and values 
of the patients [47]. Healthcare practice that involves patient activation is related with 
significantly lower primary care charges, and there has been increasing evidence for a 
relationship between patient-centred care and utilisation of medical supplies [48-49]. 
Patient-centred care may promote trust between the physician and a patient, and enhance 
patient knowledge, thereby eliminating the necessity for hospital care use, specialty 
referrals and diagnostic testing, which can negate unnecessary healthcare expenditure [49].  
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The various elements that encompass a patient-centred approach are information and 
communication, care coordination, continuity and transition, access to care, involvement of 
the family and carers, respect, emotional support and physical support [47]. Subsequently 
medication review can be regarded as an essential component of patient-centred care, and 
it has also been widely described [47, 49-51]. Although there are many definitions 
pertaining activities of a medication review, none of them are able to include all activities 
but one commonality that exists between all definitions is that the highest level necessitates 
patient involvement [50]. 
Various classifications of medication review have been derived to cater for the needs of 
patients for particular purposes. Clinical medication review addresses issues pertaining the 
patient’s medication use with regards to their clinical condition whereas prescription review 
tackles technical issues pertaining the prescription, such as anomalies or medication 
changes. Concordance and compliance review addresses issues pertaining the patient’s 
medicine-taking behaviour. It is imperative to note that the clinical medication review and 
compliance and concordance review typically require the presence of the patient, although 
all review outcomes ultimately require consent from the patient and their caregivers [51]. 
It is commendable that the pharmacist-led medication reviews that have been critically 
reviewed in this paper involve either a clinical medication review or a prescription review, 
indicating that patients were aware of their medication changes. As mentioned earlier, the 
cost savings that resulted from the pharmacist-led reviews are apparent although in view of 
enhancing the value of the service whilst saving on cost, it is worth exploring other 
opportunities to improve the clinical knowledge of pharmacists in providing effective 
medication reviews. Similar in view to comments by Spinewine et al. [31], we believe that it 
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is essential for pharmacists to undergo a systematic training structure in reviewing 
medications of older people, for instance postgraduate clinical training that is focused on 
medication optimisation in geriatrics and gerontology. This idea is strengthened based on a 
comment by Hanlon [52], who emphasised the importance of incorporating geriatric 
pharmacotherapy and pharmaceutical care at the undergraduate, postgraduate and 
continuing educational programme levels. Pharmacists training at the undergraduate level 
may not necessarily suffice, and many of the studies discussed in this paper did not include 
proper training programmes prior to the pharmacists’ reviews. Appropriate training in 
reviewing medications will add value to, and further increase the healthcare quality that 
may negate the need for additional consultations that are known to be associated with 
increased costs.  
Notwithstanding the benefits of a pharmacist’s expertise in a patient-centred approach 
while reviewing medications, the most essential outcome of patient-centredness is 
undeniably patient safety and quality care. The nascent discipline of patient safety has not 
been comprehensively defined up to date, mainly because a very fine line distinguishes 
safety and quality. While this definition may remain an exercise of semantics to some, the 
Agency of Healthcare Research and Quality has defined patient safety as “a discipline in the 
health care sector that applies safety science methods toward the goal of achieving a 
trustworthy system of health care delivery. Patient safety is also an attribute of health care 
systems; it minimises the incidence and impact of, and maximises recovery from, adverse 
events” [53]. On the other hand, the Institute of Medicine defined the quality of health care; 
“quality of care is the degree to which health care services for individuals and populations 
increase the likelihood of desired health outcomes and are consistent with current 
professional knowledge” [54]. Health care quality issues were further categorised into three 
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groups, i.e. underuse, overuse and misuse, all of which can be curbed by conducting a 
medication review exercise.  
Patient safety and high quality of care are crucial aspects of the cost-minimisation strategy. 
High quality care promotes patient safety, thereby eliminating risks of healthcare-related 
errors and adverse effects. Patients themselves have indicated preventable harm in health 
care and the impact it has inflicted upon them. The elderly are predominantly vulnerable 
and are disproportionately affected in terms of patient safety incidents and this may cause 
adverse events, which could ultimately result in trauma or even death [47, 55]; this will 
undoubtedly contribute to the increasing healthcare costs associated with this population. 
Review of the current health care system should be done in tandem to possible 
development and implementation of various programmes and interventions that have been 
described in the World Health Organization Patient Safety Tool Kit [56].  
For the reasons discussed above, government health policies should aim at investing in 
medication optimisation strategies for the older population. The strategies should leverage 
on the expertise of pharmacists at optimising medications for older people in nursing homes, 
a population that suffers from the conundrum of polypharmacy and inappropriate 
medications which have led to increased hospitalisations and healthcare expenditure. 
Pharmacists should be provided with an appropriate platform to undergo appropriate 
postgraduate clinical training to sharpen their skills. The outcomes should be measured in 
robust manners, by the conduct of proper randomised controlled trials with long study 
intervals. Assessment of relevant health quality indicators such as frailty, quality of life, 
medication burden, and cost-effectiveness of the pharmacist-led reviews in these trials will 
further support the positive impact of such interventions.  
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6. Five-year view 
The increasing evidence on cost effectiveness of medication reviews in aged care facilities 
will guide the relevant authorities to plan cost minimisation and reimbursement strategies 
for improved medication use based on economic evaluations of existing medication reviews. 
Given the concrete financial advantages in terms of decrement in total medication costs and 
associated cost savings, it is likely that the future economic evaluations will examine the 
practicality of working pharmacists and healthcare professionals to allocate time and effort 
to perform the periodic review processes in the aged care facilities and assess the possibility 
of  financial reimbursement to pharmacists for the additional time spent on performing the 
review process. To initiate this process, the incorporation of this service into a pharmacist’s 
core job in hospitals or community pharmacies should be explored.  
The future economic evaluations should aim at investing in medication optimisation 
strategies for the older population in nursing homes, a population that suffers from the 
issues related to polypharmacy and inappropriate medications which have led to increased 
hospitalisations and healthcare expenditure. A randomised controlled trial with appropriate 
study intervals offers the possibility of assessing robust cost effectiveness or cost 
minimisation measures and strategies. Another area or interest in the next few years would 
be the personalised medication management as it reduces the necessity for hospital care 
use, speciality referrals and diagnostic testing, negating unnecessary healthcare expenditure. 
 
 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 A
uc
kla
nd
 L
ibr
ary
] a
t 0
2:3
2 2
2 A
ug
us
t 2
01
7 
Ac
ce
pte
d M
an
us
cri
pt
 
7. Key issues 
• Population aging is a global phenomenon and the demand for healthcare services will 
exceed the population growth rate, given the disproportionate projected growth rate of 
older people 
• Older people residing in nursing homes are prone to polypharmacy and this may be a risk 
factor to  increased healthcare expenditure as the medication cost for older people in 
developed countries account for a large proportion of the total healthcare expenditure 
• Polypharmacy is depicted as a strong predictor of potentially inappropriate medications 
that may increase the possibility of developing adverse drug reactions which could lead to 
presentations at emergency departments of hospitals that contribute to further increase in 
healthcare expenditures 
• Pharmacist-led medication reviews promote appropriate polypharmacy, decrease the use 
of inappropriate medications, reduce hospitalisations and improve clinical outcomes 
• Cost effectiveness is an essential aspect of a medication review evaluation and the cost of 
prescribing extends beyond the cost of a medication listed on the prescription. The costs of 
prescribing, dispensing and monitoring processes should also be taken into consideration 
• This study aimed at assessing medication review based interventions conducted by 
pharmacists and this is aimed at improving medication cost savings in aged care settings 
• Most studies from the US, UK and Switzerland depicted significant (p<0.05) cost savings 
when pharmacist-led medication reviews were performed for older people residing in aged 
care facilities. However two studies from the UK and Singapore reported no significant 
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differences in cost savings when a pharmacist-led medication review was performed, 
possibly because savings from drug discontinuation were offset by the additional costs 
incurred to address new therapeutic issues  
• Clinical medication reviews, prescription reviews and concordance and compliance 
reviews require consent from the patients and caregivers, adopting a patient-centred 
approach. 
• The essential outcome of a patient centred-approach is patient safety and quality care, 
which are crucial in cost-minimisation; high quality care promotes patient safety, thereby 
eliminating risks of healthcare-related errors and adverse effects 
• Government health policies should aim at investing in medication optimisation strategies 
for older people 
Funding 
This paper was not funded. 
Declaration of Interest 
The authors have no relevant affiliations or financial involvement with any organization or 
entity with a financial interest in or financial conflict with the subject matter or materials 
discussed in the manuscript. This includes employment, consultancies, honoraria, stock 
ownership or options, expert testimony, grants or patents received or pending, or royalties. 
 
 
 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 A
uc
kla
nd
 L
ibr
ary
] a
t 0
2:3
2 2
2 A
ug
us
t 2
01
7 
Ac
ce
pte
d M
an
us
cri
pt
 
 
References  
 
1. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr 
Pharmacother 2007;5(4):345-51 
2. Odubanjo E, Bennett K, Feely J. Influence of socioeconomic status on the quality of 
prescribing in the elderly- a population based study. Br J Clin Pharmacol 2004;58:496-
502 
3. Ministry of Health Malaysia. Country Health Plan: 10th Malaysia Plan 2011-2015. 
Malaysia. Putrajaya: The Planning and Development Department; 2010 
4. Chutka DS, Takahashi PY, Hoel RW. Inappropriate medications for elderly patients. Mayo 
Clin Proc 2004;79:122-39 
5. Monane M, Matthias DM, Nagle BA, et al. Improving prescribing patterns for the elderly 
through an online drug utilization review intervention: a system linking the physician, 
pharmacist and computer. JAMA 1998;280:1249-52 
6. Da Silva DT, Santos AP, Aguiar PM, et al. Analysis of research quality regarding 
pharmaceutical intervention in elderly residents of long-term care facilities: a systematic 
review. J Am Geriatr Soc 2010;58(7):1404-06 
7. Walley T, Scott AK. Prescribing in the elderly. Postgrad Med J 1995;71(838):466-71 
8. Holmes HM, Hayley DC, Alexander GC, et al. Reconsidering medication appropriateness 
for patients late in life. Arch Intern Med 2006;166(6):605-9 
9. Wise J. Polypharmacy: a necessary evil. BMJ 2013;347:f7033 
10. Furniss L, Burns A, Craig SK, et al. Effects of a pharmacist’s medication review in nursing 
homes. Randomised controlled trial. Br J Psychiatry J Ment Sci 2000;176:563-7 
11. Zermansky AG, Alldred DP, Petty DR, et al. Clinical medication review by a pharmacist of 
elderly people living in care homes--randomised controlled trial. Age Ageing 
2006;35(6):586-91 
12. Barber ND, Alldred DP, Raynor DK, et al. Care homes’ use of medicines study: prevalence, 
causes and potential harm of medication errors in care homes for older people. Qual Saf 
Health Care 2009;18(5):341-6 
13. Somers M, Rose E, Simmonds D, et al. Quality use of medicines in residential aged care. 
Aust Fam Physician 2010 Jun; 39(6): 413–6.  
14. Dwyer LL, Han B, Woodwell DA, et al. Polypharmacy in nursing home residents in the 
United States: results of the 2004 National Nursing Home Survey. Am J Geriatr 
Pharmacother 2010;8(1):63-72 
15. Zermansky AG, Silcock J. Is medication review by primary-care pharmacists for older 
people cost effective?: a narrative review of the literature, focusing on costs and 
benefits. Pharmacoeconomics 2009;27(1):11-24 
16. Office for National Statistics. Prescriptions dispensed in the community: statistics for 
1996 to 2006 England. Leeds: NHS Information Centre, 2007. 
17. Horne R, Weinman J, Barber N, et al. Concordance, adherence and compliance in 
medicine taking: report for the National Co-ordinating Centre for NHS Service Delivery 
and Organisation R&D. London: NCCSDO, 2005. 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 A
uc
kla
nd
 L
ibr
ary
] a
t 0
2:3
2 2
2 A
ug
us
t 2
01
7 
Ac
ce
pte
d M
an
us
cri
pt
18. Jetha S. Polypharmacy, the Elderly, and Deprescribing. Consult Pharm J Am Soc Consult 
Pharm 2015;30(9):527-32 
19. Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate 
medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch 
Intern Med 1991;151(9):1825-32 
20. Beijer HJM, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a 
meta-analysis of observational studies. Pharm World Sci PWS 2002;24(2):46-54 
21. Goldberg RM, Mabee J, Chan L, et al. Drug-drug and drug-disease interactions in the ED: 
analysis of a high-risk population. Am J Emerg Med 1996;14(5):447-50  
22. Wasserfallen J, Livio F, Buclin T, et al. Rate, type, and cost of adverse drug reactions in 
emergency department admissions. Eur J Intern Med 2001;12:442-7 
23. Wu WK, Pantaleo N. Evaluation of outpatient adverse drug reactions leading to 
hospitalization. Am J Health Syst Pharm 2003;60:253-9 
24. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized 
patients. Adverse Drug Events Prevention Study Group. JAMA 1997;277:307-11 
25. Cullen DJ, Sweitzer BJ, Bates DW, et al. Preventable adverse drug events in hospitalized 
patients: A comparative study of intensive care and general care units. Crit Care Med 
1997;25:1289-97 
26. Field TS, Gilman BH, Subramanian S, et al. The costs associated with adverse drug events 
among older adults in the ambulatory setting. Med Care 2005;43:1171-6 
27. Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: 
how well can it be measured and optimised? Lancet 2007;370(9582):173-184 
28. Christensen D, Trygstad T, Sullivan R, et al. A pharmacy management intervention for 
optimizing drug therapy for nursing home patients. Am J Geriatr Pharmacother 
2004;2(4):248-56  
29. Task Force on Medicines Partnership. Room for review: A guide to medication review: 
the agenda for patients, practitioners and managers [Internet]. London: Task Force on 
Medicines Partnership The National Collaborative Medicines Management Services 
Programme; 2002 [cited 2017 May 30]. Available from: 
http://myweb.tiscali.co.uk/bedpgme/CG/Room%20for%20Review%20-
%20Medication%20review.pdf 
30. Parsons C, Alldred D, Daiello L, et al. Prescribing for older people in nursing homes: 
strategies to improve prescribing and medicines use in nursing homes. Int J Older People 
Nurs 2011;6(1):55-62  
31. Spinewine A, Fialová D, Byrne S. The role of the pharmacist in optimizing 
pharmacotherapy in older people. Drugs Aging 2012;29(6):495-510  
32. Wendy Clyne, Blenkinsopp A, Seal R. A guide to medication review [Internet]. United 
Kingdom: National Prescribing Centre, Department of Health, National Health Service; 
2008 [cited 2017 May 30]. Available from: http://www.cff.org.br/userfiles/52%20-
%20CLYNE%20W%20A%20guide%20to%20medication%20review%202008.pdf   
33. The Department of Health. Medication management reviews [Internet]. Australian 
Government Department of Health and Ageing; 2014 [cited 2017 May 30]. Available 
from: 
http://www.health.gov.au/internet/main/publishing.nsf/Content/medication_managem
ent_reviews.htm  
34. American Pharmacists Association and National Association of Chain Drug Stores 
Foundation. Medication therapy management in pharmacy practice: core elements of an 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 A
uc
kla
nd
 L
ibr
ary
] a
t 0
2:3
2 2
2 A
ug
us
t 2
01
7 
Ac
ce
pte
d M
an
us
cri
pt
MTM service model [Internet]. United States of America: American Pharmacists 
Association and National Association of Chain Drug Stores Foundation; 2008 Mar [cited 
2017 May 30]. Available from: 
http://www.pharmacist.com/sites/default/files/files/core_elements_of_an_mtm_practi
ce.pdf  
35. Pharmacy Council of New Zealand. Medicines management: definition, levels, 
competence framework [Internet]. Pharmacy Council of New Zealand; 2006 [cited 2017 
May 30]. Available from: 
http://www.pharmacycouncil.org.nz/cms_show_download.php?id=124  
36. Government of Ontario. MedsCheck - Public Information - Ministry of Health and Long-
term Care [Internet]. [cited 2017 May 30]. Available from: 
http://www.health.gov.on.ca/en/public/programs/drugs/medscheck/  
37. Hatah E, Braund R, Tordoff J, et al. A systematic review and meta-analysis of pharmacist-
led fee-for-services medication review. Br J Clin Pharmacol 2014;77(1):102-15 
38. Milos V, Rekman E, Bondesson Å, Eriksson T, Jakobsson U, Westerlund T, et al. Improving 
the quality of pharmacotherapy in elderly primary care patients through medication 
reviews: a randomised controlled study. Drugs Aging 2013;30(4):235-46.  
39. Lapane KL, Hughes CM, Christian JB, Daiello LA, Cameron KA, Feinberg J. Evaluation of 
the fleetwood model of long-term care pharmacy. J Am Med Dir Assoc 2011;12(5):355-
63.  
40. Patterson SM, Hughes CM, Crealey G, Cardwell C, Lapane KL. An evaluation of an 
adapted U.S. model of pharmaceutical care to improve psychoactive prescribing for 
nursing home residents in northern ireland (fleetwood northern ireland study). J Am 
Geriatr Soc 2010;58(1):44-53.  
41. Trygstad TK, Christensen D, Garmise J, et al. Pharmacist response to alerts generated 
from Medicaid pharmacy claims in a long-term care setting: results from the North 
Carolina polypharmacy initiative. J Manag Care Pharm 2005;11(7):575-83 
42. Trygstad TK, Christensen DB, Wegner SE, et al. Analysis of the North Carolina long-term 
care polypharmacy initiative: a multiple-cohort approach using propensity-score 
matching for both evaluation and targeting. Clin They 2009;31(9):2018-37 
43. Bulhart MI, Wermeille JP. Multidisciplinary medication review: evaluation of a 
pharmaceutical care model for nursing homes. Int J Clin Pharm 2011;33(3):549-57 
44. Baqir W, Barrett S, Desai N, et al. A clinico-ethical framework for multidisciplinary review 
of medication in nursing homes. BMJ Qual Improv Report 
2014;3:doi:10.1136/bmjquality.u203261.w2538 
45. Chia HS, Ho JA, Lim BD. Pharmacist review and its impact on Singapore nursing homes. 
Singapore Med J 2015 Sept;56(9):493-501 
46. Charmel P, Frampton S. Building the business case for patient-centered care. Healthc 
Financ Manage 2008;62(3):80-5 
47. Australian Commission on Safety and Quality in Healthcare (2011). Patient-centred care: 
Improving quality and safety through partnerships with patients and consumers. 
Australia: Australian Commission on Safety and Quality in Healthcare. Retrieved from 
http://www.safetyandquality.gov.au/wp-
content/uploads/2012/03/PCC_Paper_August.pdf 
48. Bertakis KD, Azari R, Callahan EJ, et al. The impact of physician practice style on medical 
charges. J Fam Pract 1999;48:31-6 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 A
uc
kla
nd
 L
ibr
ary
] a
t 0
2:3
2 2
2 A
ug
us
t 2
01
7 
Ac
ce
pte
d M
an
us
cri
pt
49. Bertakis KD, Azari R. Patient-centered care is associated with decreased health care 
utilization. J Am Board Fam Med 2011;24(3):229-39 
50. Geurts, MME, Talsma J, Brouwers JRBJ, et al. Medication review and reconciliation with 
cooperation between pharmacist and general practitioner and the benefit for the 
patient: a systematic review. Br J Clin Pharmacol 2012;74(1):16-33 
51. NHS Cumbria Medicines Management Team. Clinical Medication Review: A Practice 
Guide. [Internet]. United Kingdom: NHS Cumbria Medicines Management Team; 2013 
Feb [cited 2017 Jun 1]. Available from: 
http://www.cumbria.nhs.uk/ProfessionalZone/MedicinesManagement/Guidelines/Medi
cationReview-PracticeGuide2011.pdf 
52. Hanlon JT. Perspective: is pharmacy ready for the baby boomers? Am J Geriatr 
Pharmacother 2010;8(1):1-3 
53. Emanuel L, Berwick D, Conway J, et al. (2008). What Exactly Is Patient Safety? In K. 
Henriksen, J. B. Battles, M. A. Keyes, & M. L. Grady (Eds.), Advances in Patient Safety: 
New Directions and Alternative Approaches (Vol. 1: Assessment). Rockville (MD): Agency 
for Healthcare Research and Quality. Retrieved from 
http://www.ncbi.nlm.nih.gov/books/NBK43629/ 
54. Chassin MR, Galvin RW. The urgent need to improve health care quality. Institute of 
Medicine National Roundtable on Health Care Quality. JAMA 1998;280(11),1000-5.  
55. World Health Organization. (2016). Patients for Patient Safety – Statement of Case. 
Retrieved June 1 2017, from 
http://www.who.int/patientsafety/patients_for_patient/statement/en/ 
56. World Health Organization. (2015). Patient safety tool kit. Egypt: World Health 
Organisation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 A
uc
kla
nd
 L
ibr
ary
] a
t 0
2:3
2 2
2 A
ug
us
t 2
01
7 
